Preservation of Neurocognition after Proton Beam Radiation Therapy for Intracranial Tumors: First Results from REGI-MA-002015.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 04 2023
Historique:
received: 17 02 2022
revised: 26 09 2022
accepted: 27 09 2022
pubmed: 14 11 2022
medline: 21 3 2023
entrez: 13 11 2022
Statut: ppublish

Résumé

Proton beam radiation therapy reduces dose to healthy brain tissue and thereby decreases the risk of treatment-related decline in neurocognition. Considering the paucity of prospective data, this study aimed to evaluate neurocognitive performance in an adult patient population with intracranial tumors. Between 2017 and 2021, patients enrolled in the MedAustron registry study and irradiated for intracranial tumors were eligible for neurocognitive assessment. Patients with available 1-year follow-up data were included in the analysis. The test battery consisted of a variety of standardized tests commonly used in European Organization for Research and Treatment of Cancer trials. Scores were transformed into z scores to account for demographic effects, and clinically relevant change was defined as a change of ≥1.5 standard deviations. Binary logistic regression analysis and the χ One hundred twenty-three patients with mostly nonprogressive, extra-axial tumors and neurocognitive assessment at baseline and treatment end as well as 3, 6, and 12 months after completion of proton beam radiation therapy were analyzed. Overall, 7 test scores revealed stability in neurocognitive function with minimal positive changes 1 year after treatment completion (statistically significant in 6 of 7 tests), whereas the majority had no or minimal baseline deficits. At 1-year follow-up, 89.4% of all patients remained stable in their overall cognitive functioning without clinically relevant deterioration in 2 or more tests. None of them showed disease progression. Of the patients, 8.1% presented with radiation-induced brain lesions and exhibited a higher percentage of overall cognitive deterioration without reaching statistical significance. Multivariate binary logistic regression analysis revealed higher age at baseline as the only independent parameter to be associated with an overall clinically relevant cognitive decline. There was no significant correlation of hippocampal doses and memory functioning. One year after proton therapy, we observed preservation of cognitive functioning in the vast majority of our patients with intracranial tumors.

Identifiants

pubmed: 36372610
pii: S0360-3016(22)03418-6
doi: 10.1016/j.ijrobp.2022.09.081
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102-1114

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Birgit Flechl (B)

EBG MedAustron GmbH, Wiener Neustadt, Austria.

Lisa Konrath (L)

EBG MedAustron GmbH, Wiener Neustadt, Austria. Electronic address: lisa.konrath@medaustron.at.

Carola Lütgendorf-Caucig (C)

EBG MedAustron GmbH, Wiener Neustadt, Austria.

Milana Achtaewa (M)

EBG MedAustron GmbH, Wiener Neustadt, Austria.

Eugen B Hug (EB)

EBG MedAustron GmbH, Wiener Neustadt, Austria.

Petra Georg (P)

EBG MedAustron GmbH, Wiener Neustadt, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH